Type 2 diabetes prevention: A review

Clinical Diabetes

Volumn 28, Issue 2, 2010, Pages 53-59

  Ahmad, Leena A ^a   Crandall, Jill P ^b  

^a Department of Medicine

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; GLUCOSE; METFORMIN; PLACEBO; ROSIGLITAZONE; TROGLITAZONE;

BARIATRIC SURGERY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FRACTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; LIFESTYLE MODIFICATION; LIVER TOXICITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PREGNANCY DIABETES MELLITUS; PUBLIC HEALTH PROBLEM; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77954696867     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.28.2.53     Document Type: Review

References (41)

1. American Diabetes Association: Diabetes statistics [article online]. Available from www.diabetes.org/diabetes-basics/diabetes-statistics. Accessed 22 February 2010
2. Dall T, Mann SE, Zhang Y, Martin J, Chen Y, Hogan P: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 31:596-615, 2008
3. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction in the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2008
4. Norris SL, Zhang X, Avenell A, Gregg E, Bowman B, Schmid CH, Lau J: Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews 2005, CD005270.dol:10.1002/14651858.CD005270
5. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
6. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow up study. Lancet 371:1783-1789, 2008
7. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
8. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow up of the Finnish Diabetes Prevention Study. Lancet 368:1673-1679, 2006
9. DPP Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
10. DPP Research Group: The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Bio Sci Med Sci 61:1075-1081, 2006
11. DPP Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374:1677-1686, 2009
12. Kosaka K, Noda M, Kuzuya T: Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67:152-162, 2005
13. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V: The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDDP-1). Diabetologia 49:289-297, 2006
14. Sjostrom L: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
15. Sjostrom L: Surgical treatment of obesity: an overview of the results from the SOS study. In Handbook of Obesity: Clinical Applications. Bray GA, Bouchard C, Eds. New York, Marcel Dekker, 2003
16. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316-323, 2008
17. Dixon AF, Dixon JB, O'Brien PE: Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90:813-819, 2005
18. Yang W, Lin L, Qi J, Yu Z, Pei H, He G, Yang Z, Wang P, Li G, Pan X: The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17:131-136, 2001
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOPNIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
20. DPP Research Group: Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
21. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
22. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR; DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105, 2006
23. Nissen SE, Wolski K.: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007
24. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006
25. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardio vascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM Trial. JAMA 290:486-494, 2003
26. DPP Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28:888-894, 2005
27. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE for the DPP Research Group: The cost effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142:323-332, 2005
28. Eddy DM, Schlessinger L, Kahn R: Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143:251-264, 2005
29. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z: Cost effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30:2548-2552, 2007
30. Vijgen SM, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL: Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 24:425-44, 2006
31. Absetz P, Valve R, Oldenberg B, Heinonen H, Nissinen A, Fogelholm M, Ilvesmaki V, Talja M, Ututela A: Type 2 diabetes prevention in the "real world": one-year results of the GOAL implementation trial. Diabetes Care 30:2465-2470, 2007
32. Uutela A, Absetz P, Nissinen A, Valve R, Talja M and Fogelholm M: Health psychological theory in promoting population health in Paijat-Hame, Finland: first steps toward a type 2 diabetes prevention study. J Health Psychol 9:73-84, 2004
33. Absetz P, Oldenberg B, Hankonen N, Valve R, Heinonen H, Nissinen A, Folgelholm M, Talja M, Ututela A.: Type 2 diabetes Prevention in the "real world": three-year results of the GOAL Lifestyle implementation Trial. Diabetes Care 32:1418-1420, 2009
34. Ackermann RT, Marrero DG: Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community. Diabetes Care 33:69-78, 2007
35. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG: Translating the Diabetes Prevention Program into the community: the DEPLOY Pilot Study. Am J Prev Med, 35:357-363, 2008
36. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT: Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: the DEPLOY pilot study. Diabetes Care 32:394-396, 2009
37. DPP Research Group: Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care 26:36-47, 2003
38. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, Engelgau MM, Ratner RE, Herman WH: An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care 29:1237-1241, 2006
39. Jackson L: Translating the Diabetes Prevention Program into practice: a review of community interventions. Diabetes Educ 35:309-320, 2009
40. Amundson H, Butcher M, Gohdes D, Hall T, Harwell T, Helgerson S, Vanderwood K: Translating the Diabetes Prevention Program into practice in the general community. Diabetes Educ 35:209-223, 2009
41. American Diabetes Association: Standards of medical care in diabetes-2010 Diabetes Care 32:S11-S61, 2010.